1-3 of 3
Susan J McCall, MSN ANP-BC
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study Combining Ibrutinib with Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL): NCI-Cancer Therapeutics Evaluation Program (CTEP) #9588

Craig S. Sauter, MD, Stephanie L. Verwys, Susan J. McCall, MSN ANP-BC, Shoshana T. Miller, Amanda I. Courtien, Heiko Schoder, MD, Pamela Harris, MD, Matthew J. Matasar, MD MS, Anas Younes, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2016) 128 (22): 4198.
https://doi.org/10.1182/blood.V128.22.4198.4198
Published: 2016
Journal Articles

Risk Factors Predicting Outcomes for Primary Refractory Hodgkin Lymphoma Patients Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation

Gunjan L Shah, MDMS, Kurt S Bantilan, MPH, Stephanie L Verwys, BS, Susan J McCall, MSN ANP-BC, Joachim Yahalom, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Craig H. Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 520.
https://doi.org/10.1182/blood.V126.23.520.520
Published: 2015
Journal Articles

TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin

Alison J Moskowitz, MD, Sun Cho, Martin Fleisher, PhD, Kaitlin M Woo, MS, Zhigang Zhang, PhD, Stephanie Fox, Susan J McCall, MSN ANP-BC, Heiko Schoder, MD, Joachim Yahalom, MD, Craig H Moskowitz, MD
Journal: Blood
Blood (2015) 126 (23): 180.
https://doi.org/10.1182/blood.V126.23.180.180
Published: 2015